KA
HZNP

Kovack Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kovack Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,040
Closed -$220K – 839
2021
Q4 		$220K Hold
2,040
– – 0.02% 630
2021
Q3 		$223K Buy
+2,040
New +$212K 0.02% 627

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kovack Advisors's HZNP Position: Q1 2022 in Review

Kovack Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 2,040 shares — an estimated $220K sold.

Kovack Advisors first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $223K in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • Kovack Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Kovack Advisors sold 2,040 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $220K.
  • Kovack Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Kovack Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $223K in Q3 2021.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Kovack Advisors's 13F filing for Q1 2022, filed 16 May 2022.